|By PR Newswire||
|April 4, 2014 08:01 AM EDT||
NEW YORK, April 4, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Intuitive Surgical, Inc. (NASDAQ: ISRG), Agilent Technologies Inc. (NYSE: A), C.R. Bard, Inc. (NYSE: BCR), St. Jude Medical, Inc. (NYSE: STJ), and Stryker Corporation (NYSE: SYK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Intuitive Surgical, Inc. Analyst Notes
On April 1, 2014, Intuitive Surgical, Inc. (intuitive Surgical) announced the FDA clearance and introduction of da Vinci Xi Surgical System, a technological innovation in replacing large-incision abdominal surgeries (open surgery) with a minimally invasive approach, in the U.S. According to the Company, the da Vinci Xi System has broader capabilities than prior generations of the da Vinci System. Commenting on the development, Gary Guthart, Intuitive Surgical President and CEO, remarked, "Our goal is to develop technology that enhances surgical performance. The da Vinci Xi System's new overhead architecture means that multi-quadrant surgery can be performed without repositioning the system, an innovation long sought by surgeons who perform complex procedures. We strive to provide the most advanced, least invasive option for surgery, and we are working hard to make minimally invasive surgery the standard of care." The Company stated that it will seek regulatory clearances to market the da Vinci Xi System around the world. The full analyst notes on Intuitive Surgical, Inc. are available to download free of charge at:
Agilent Technologies Inc. Analyst Notes
On April 1, 2014, Agilent Technologies Inc. (Agilent) announced a quarterly dividend in the amount of c.$0.13 per share of common stock. Agilent informed that the dividend will be paid on April 23, 2014 to shareholders of record at the close of business on April 11, 2014. The full analyst notes on Agilent Technologies Inc. are available to download free of charge at:
C.R. Bard, Inc. Analyst Notes
On April 1, 2014, C.R. Bard, Inc. (Bard) announced that it will discuss its Q1 2014 operating results and provide guidance for Q2 2014 via a conference call to be hosted by the Company on Tuesday, April 22, 2014 at 5:00 p.m. EDT. The Company stated that it will issue an earnings press release after the market closes on the same day. Bard added that the call will be webcast via its website, where it will be available for future on-demand replay. The full analyst notes on C.R. Bard, Inc. are available to download free of charge at:
St. Jude Medical, Inc. Analyst Notes
On March 24, 2014, St. Jude Medical, Inc. (St. Jude Medical) announced the global launch of the Optisure™ Defibrillation Lead as the latest addition to its Optim™ lead family. Commenting on the launch, Dr. Raymond H. M. Schaerf, a thoracic and cardiac surgeon at Providence Saint Joseph Medical Center, said, "The Optisure lead has a thicker layer of Optim insulation that adds additional abrasion resistance to a lead that has already demonstrated excellent safety and reliability, backed by clinical evidence from St. Jude Medical as well as large, independent, multi-center studies." St. Jude Medical added that the Optisure Defibrillation Lead is also compatible with all of the Company's implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), including the next-generation Ellipse™ and SJM Assura™ portfolio of ICDs and CRT-Ds. The full analyst notes on St. Jude Medical, Inc. are available to download free of charge at:
Stryker Corporation Analyst Notes
On March 31, 2014, Stryker Corporation (Stryker) announced that Curtis E. Hall, Vice President and Chief Legal Officer, has chosen to move to a part-time role as Senior Legal Counsel, and transition the leadership of the Company's Legal and Compliance function to Michael D. Hutchinson, General Counsel. The Company stated that Hutchinson will expand his role to include Corporate Compliance and the Corporate Secretary function and will become a part of Stryker's Executive Leadership Team. Commenting on the changes, Stryker President and CEO, Kevin A. Lobo, stated, "I would like to thank Curtis for his many contributions to Stryker throughout his career, including building the global legal and compliance organizations. He has demonstrated consistently strong judgment, leadership and commitment to the growth of the Company." Lobo added, "Mike has demonstrated outstanding leadership and business partnering skills, and has been working closely with Curtis to allow for a smooth transition into this new role. I am very pleased to have him join Stryker's Executive Leadership Team." The full analyst notes on Stryker Corporation are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Sep. 28, 2016 09:15 PM EDT Reads: 331
Sep. 28, 2016 08:30 PM EDT Reads: 434
Sep. 28, 2016 08:30 PM EDT Reads: 1,711
Sep. 28, 2016 08:15 PM EDT Reads: 325
Sep. 28, 2016 07:00 PM EDT Reads: 1,626
Sep. 28, 2016 06:45 PM EDT Reads: 4,150
Sep. 28, 2016 06:30 PM EDT Reads: 3,111
Sep. 28, 2016 06:15 PM EDT Reads: 286
Sep. 28, 2016 06:00 PM EDT Reads: 1,773
Sep. 28, 2016 05:15 PM EDT Reads: 250
Sep. 28, 2016 05:15 PM EDT Reads: 247
Sep. 28, 2016 05:00 PM EDT Reads: 1,724
Sep. 28, 2016 04:30 PM EDT Reads: 2,815
Sep. 28, 2016 04:15 PM EDT Reads: 2,438
Sep. 28, 2016 04:15 PM EDT Reads: 1,879